title: Treatment: Outcome and Toxicity of Volumetric Modulated Arc Therapy in Oropharyngeal Carcinoma.
abstract: OBJECTIVE
  Radiotherapy is a common approach for treating squamous cell carcinoma (SCC) of the oropharynx. We aimed to analyze toxicity and outcome of patients affected by oropharyngeal SCC treated with volumetric modulated arc therapy (VMAT).
  
  
  METHODS
  Fifty-four patients presenting advanced orophayngeal carcinoma who were treated with radical radiotherapy were analyzed. All patients were treated with VMAT-RapidArc, with simultaneous integrated boost in 33 fractions for a dose of 69.96 Gy to the high-risk, and of 54.45 Gy to the low-risk volume.
  
  
  RESULTS
  Median follow-up was 23 months. In eight cases, locoregional relapse was observed (median time to relapse=10.7 months). Four among eight local recurrences appeared in the high-dose target volume. The 1- and 2-year actuarial disease-free survival rates were 88% and 80%, respectively. The 1- and 2-year actuarial overall survival rates were 94% and 87%, respectively.
  
  
  CONCLUSIONS
  VMAT for oropharyngeal SCC treatment is effective and safe, with interesting rates of control of disease and survival.
authors.affiliation: Department of Radiotherapy and Radiosurgery, Humanitas University, Milan, Italy.
authors.forename: Ciro
authors.initials: C
authors.lastname: Franzese
authors.affiliation: Department of Radiotherapy and Radiosurgery, Humanitas University, Milan, Italy antonella.fogliata@humanitas.it.
authors.forename: Antonella
authors.initials: A
authors.lastname: Fogliata
authors.affiliation: Department of Radiotherapy and Radiosurgery, Humanitas University, Milan, Italy.
authors.forename: Davide
authors.initials: D
authors.lastname: Franceschini
authors.affiliation: Department of Radiotherapy and Radiosurgery, Humanitas University, Milan, Italy.
authors.forename: Elena
authors.initials: E
authors.lastname: Clerici
authors.affiliation: Department of Radiotherapy and Radiosurgery, Humanitas University, Milan, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: D'Agostino
authors.affiliation: Department of Radiotherapy and Radiosurgery, Humanitas University, Milan, Italy.
authors.forename: Piera
authors.initials: P
authors.lastname: Navarria
authors.affiliation: Department of Radiotherapy and Radiosurgery, Humanitas University, Milan, Italy.
authors.forename: Pietro
authors.initials: P
authors.lastname: Mancosu
authors.affiliation: Department of Radiotherapy and Radiosurgery, Humanitas University, Milan, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Tomatis
authors.affiliation: Department of Radiotherapy and Radiosurgery, Humanitas University, Milan, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Cozzi
authors.affiliation: Department of Radiotherapy and Radiosurgery, Humanitas University, Milan, Italy Department of Biomedical Sciences, Humanitas University, Milan, Italy.
authors.forename: Marta
authors.initials: M
authors.lastname: Scorsetti
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy*; D000068818:Cetuximab / Q000008:administration & dosage; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D019583:Dose Fractionation, Radiation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009959:Oropharyngeal Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D011855:Radiodermatitis / Q000209:etiology; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects*; D016896:Treatment Outcome; D014987:Xerostomia / Q000209:etiology
chemical_list: D016190:Carboplatin; D000068818:Cetuximab; D002945:Cisplatin; D005472:Fluorouracil
keywords: Oropharynx; radiation therapy; simultaneous integrated boost; volumetric modulated arc therapy